You are here

  • Home
  • Archive
  • Volume 12, Issue 1
  • Intratumoral administration of the immunologic adjuvant AS01B in combination with autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma

Citation Tools

Article menu
Oncolytic and local immunotherapy
Original research
Intratumoral administration of the immunologic adjuvant AS01B in combination with autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Tijtgat J, Geeraerts X, Boisson A, et al
Intratumoral administration of the immunologic adjuvant AS01B in combination with autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma
Journal for ImmunoTherapy of Cancer 2024;12:e008148. doi: 10.1136/jitc-2023-008148